

FAX TRANSMISSION

From The
LAW OFFICES OF
TOWNSEND & TOWNSEND & CREW
Patents, Trademarks, Copyrights, Antitrust, Commercial Litigation

Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
Tel: 415 576-0200
Fax: 415 576-0300

TELECOPIER COVER SHEET

IMPORTANT: This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and/or exempt from disclosure by applicable law or court order. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is **strictly prohibited**. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above San Francisco address via the United States Postal Service. Thank you.

To: Dr. Ron Schwadron

Date: November 3, 1997

Fax #: 703-305-7939

Pages: 15, including this cover sheet. If you have any problems with reception please call extension 4225.

From: Timothy L. Smith

Re: Ser. No. 08/349,177
Our File: 018623-005840US

OFFICIAL COMMUNICATION: Please deliver to Examiner Schwadron (Group 1816) immediately.

OK to

Enter
vss
11/4/97
#17/C
RSP
11/17/97

CERTIFICATE OF FACSIMILE TRANSMISSION
I hereby certify that this correspondence is being
facsimile transmitted to the Patent and Trademark Office
(Fax No. (703) 305-7939)

on November 3, 1997
(Date)

TOWNSEND and TOWNSEND and CREW LLP

By Timothy L. Smith

PATENT

Attorney Docket No. 018623-005840US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Howard M. Grey *et al.*

Examiner: Ronald B. Schwadron

Serial No.: 08/349,177

Art Unit: 1816

Filed: December 2, 1994

For: HLA-A2.1 BINDING PEPTIDES
AND THEIR USES

**RESPONSE TO
COMMUNICATION**

Assistant Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In response to the Office communication mailed on October 1, 1997, Applicants respectfully submit the following amendments and remarks.

Please amend the application as follows:

In the Claims:

Please add the following new claims 37-55:

37. A ~~composition~~ comprising an isolated immunogenic peptide having an HLA-A2.1 binding motif, which binding motif has about 9 or 10 residues: